Skip to main
IBRX
IBRX logo

ImmunityBio (IBRX) Stock Forecast & Price Target

ImmunityBio (IBRX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ImmunityBio reported a significant 21% increase in Q4 2024 net product revenue to $7.2 million, driven by accelerating sales of its product candidate ANKTIVA following FDA approval. The company demonstrates strong clinical efficacy with a durable disease-free survival rate of 51.1% and ongoing improvements in complete response rates, highlighting the potential for ANKTIVA's application in treating non-muscle invasive bladder cancer. Additionally, strategic collaborations, such as with the Serum Institute of India, alongside successful submissions for regulatory approvals in Europe, position ImmunityBio for substantial revenue growth projected to reach $137.4 million by 2025 and $4.3 billion by 2034.

Bears say

ImmunityBio has consistently reported operating losses since its inception, indicating a potential struggle to achieve profitability in the foreseeable future. The company's financial flexibility is further hampered by its debt and revenue interest liabilities, which could adversely affect cash flows and limit opportunities for raising additional capital. Additionally, regulatory approval challenges and declining response rates for its therapies may contribute to investor skepticism, exacerbating negative sentiment surrounding the stock.

ImmunityBio (IBRX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ImmunityBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ImmunityBio (IBRX) Forecast

Analysts have given ImmunityBio (IBRX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, ImmunityBio (IBRX) has a Strong Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ImmunityBio (IBRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.